Ares Financial Consulting’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$885 Hold
3
– – ﹤0.01% 988
2026
Q2
$680 Hold
3
– – ﹤0.01% 1060
2026
Q1
$525 Hold
3
– – ﹤0.01% 1015
2025
Q4
$598 Buy
+3
New +$544 ﹤0.01% 834

Other funds holding CRL

Ares Financial Consulting's CRL Position: Q3 2026 in Review

Ares Financial Consulting held its Charles River Laboratories (CRL) position steady in Q3 2026 at 3 shares worth $885. The position accounts for ﹤0.01% of the portfolio, ranked #988.

Ares Financial Consulting first reported a position in CRL in Q4 2025 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Ares Financial Consulting held 3 shares of Charles River Laboratories worth $885 as of Q3 2026.
  • Ares Financial Consulting left its Charles River Laboratories share count unchanged in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #988 holding.
  • Ares Financial Consulting first reported a position in Charles River Laboratories in Q4 2025 and has held it in 4 quarters since.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.